Search clinical trials for: PF-04191834 placebo

Total 54252 results

Pfizer

Withdrawn

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

Healthy
Pfizer

Terminated

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

Osteoarthritis, Knee

United States, Sweden, Canada
Pfizer

Completed

To Test The Relative Bioavailability Of PF-04191834 When Dosed As An Immediate Release Tablet Compared With Solution Following Single And Multiple Dosing

Asthma

Belgium
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

Healthy

United States
Pfizer

Completed

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Healthy | Chronic Rhinosinusitis With Nasal Polyps | Atopic Dermatitis

United States
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Pfizer

Completed

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Anorexia | Breast Cancer | Fatigue | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Cachexia | Non-small Cell Lung Cancer | Loss of Appetite

United States, Canada
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Terminated

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Active, not recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Spain, Belgium, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, France, Italy, United Kingdom, Russian Federation, Israel, Switzerland
Pfizer

Completed

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Healthy

United States
Pfizer

Completed

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

Healthy Participants

United States
Pfizer

Completed

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Healthy | Sickle Cell Anemia

United States
Pfizer

Completed

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Healthy

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Cannabis Dependence

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Healthy

Belgium
Pfizer

Terminated

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Australia, Canada, United Kingdom, Japan, Bulgaria, Italy, Poland
University of Zurich
Pfizer

Completed

Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals

Decision Making

Switzerland
Pfizer

Completed

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

Healthy

Belgium
Pfizer

Completed

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Healthy

United States
Biogen

Completed

First-in-Human Study of PF-04958242 in Healthy Volunteers

Healthy Volunteer

Singapore
Pfizer

Terminated

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

Asthma

United States
Pfizer

Completed

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Healthy Subjects

United States, Belgium
Pfizer

Completed

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Non-alcoholic Fatty Liver Disease

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects

Healthy Volunteers

Belgium
Pfizer

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

Healthy Subjects

United States
Pfizer

Withdrawn

Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

Acne Vulgaris
Pfizer

Completed

A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

Healthy

Belgium
Pfizer

Completed

Cold Pressor Test is Used in This Study to Assess the Effect of PF-06305591 on Pain Intensity Evoked by Cold in Healthy Male Subjects

Healthy

Belgium
Pfizer

Completed

PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions

Healthy

United States
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

Pharmacokinetics | Safety | Phase 1 | Single Dose | Toleration

Belgium
Pfizer

Completed

Single Dose Escalation Study of PF-05190457 in Healthy Volunteers

Diabetes Mellitus, Type II

Belgium
Pfizer

Completed

A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer

Completed

A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth

Healthy

Singapore
Pfizer

Completed

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Schizophrenia

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous

United States, Spain, Taiwan, Canada, Greece
Pfizer

Recruiting

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Healthy

United States, Belgium
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru

3

Subscribe